



MOWOOT becomes the first Spanish/Catalan Medtech company featured on EIT Health's digital venture capital & crowdfunding platform

Europe's main crowdfunding platforms specialized in healthcare, Aescuvest and Capital Cell, join forces and collaborate for the first time under EIT Health initiative to support MOWOOT's EU expansion.

Barcelona, 9th of November of 2021

The 2 biggest European platforms specialized in attracting investment for companies in the health sector, Aescuvest (Germany) and Capital Cell (Spain) sign a collaboration agreement to jointly launch a crowdfunding campaign with the goal of 2,000,000 euros for the company MOWOOT.

With this, the company MOWOOT, founded in 2014 in Barcelona and specialized in the design and sale of medical devices, is the first ever company to simultaneously launch a pan-European fundraising campaign on both these platforms, supported by EIT Health.

Thanks to this unique collaboration, European investors of any size can invest in MOWOOT via equity-crowdfunding with the tranquility of knowing the project has been reviewed and validated independently by both platforms, taking into account scientific and financial information, by international experts.

With the funding obtained, the company aims to boost its expansion plan focused on the main European markets.

"We are very proud to be the first company ever to launch a funding campaign in collaboration with the 2 biggest European crowdfunding and digital venture capital platforms specialized in health, Aescuvest and Capital Cell. This collaboration reflects the international importance of our project and will provide us the funds necessary to further expand in Europe." says Dr. Markus Wilhelms, CEO & cofounder of MOWOOT.

"We are especially happy that this crowdfunding is an opportunity for small investors, like patients and medical professionals who have experienced the benefits of MOWOOT first hand, to also form part of the financial success of our company."

In opinion of GENESIS Biomed, consultant and investor in MOWOOT, this campaign highlights the potential interest of this project for investors. A medical device already in the market that solves an unmet clinical need facilitating intestinal transit in people with chronic constipation.

MOWOOT has been accelerated and awarded by EIT Health on several occasions and this fundraising campaign is yet another seal of excellence for the clear value that the company offers to patients, healthcare professionals and investors alike. This year MOWOOT has been selected to receive support in reaching markets in Europe and beyond as part of EIT Health's Bridgehead program.



MOWOOT

MOWOOT™ (legal name usMIMA S.L.) was founded in 2014 after the founder team (Dr. Markus Wilhelms, Dr. Immaculada Herrero, Dr. Angel Calzada & Marc Benet) detected an unmet clinical need in the management of slow intestinal transit disorders during the MOEBIO European Stanford *BioDesign* program 'dHealth Barcelona', with the aim of improving the quality of life of people suffering from chronic constipation.

Currently it is estimated that 1 in 5 adults suffers from chronic constipation. This translates into 250 million people in Europe and the United States alone and generates an annual cost of 100 billion euros for the healthcare systems. The prevalence is especially high in patients with neurological diseases (up to 80%), such as spinal cord injury, multiple sclerosis, and Parkinson's disease, and in the elderly (up to 60%).

Current solutions are pharmacological, such as laxatives, or invasive, such as enemas and surgical procedures, and are not indicated for chronic use due to their side effects and high costs.

MOWOOT is the first non-pharmacological and non-invasive solution for chronic constipation without the side effects of current approaches and was developed in collaboration with the leading neuro-rehabilitation hospital Institut Guttmann in Barcelona.

To date, MOWOOT has raised over 3,800,000 euros of private and public funding, which was dedicated to the development, IP protection, clinical evaluation and CE certification of the product "MOWOOT-II Intestinal Transit Management System". The product is on the market since 2018 and already recommended in clinical guidelines and reimbursed by private and public healthcare providers in different European markets.

Currently, MOWOOT's most important market is Germany, representing up to 40% of Europe's medical device market, and in 2019 the German medical device distributor 4M Medical has invested in the company, highlighting the products potential in this market.

For more information visit: <https://www.mowoot.com/en/>

Aescuvest, powered by EIT Health

Aescuvest is a Germany based digital venture capital & crowdfunding platform supported by EIT Health which enables great health innovations through equity investments. It is the leading platform to foster and fund smart healthcare ideas. This independent launch pad offers financing strategies to companies & an above-average profit share to investors.

For more information visit: <https://projects.aescuvest.eu/mowoot/>.

EIT Health

EIT Health is a network of best-in-class health innovators with approximately 150 partners and is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. EIT Health collaborates across borders to deliver new solutions that can enable European citizens to live longer, healthier lives.

As Europeans tackle the challenge of increasing chronic diseases and multi-morbidity and seek to realize the opportunities that technology offers to move beyond conventional approaches to treatment, prevention and healthy lifestyles, we need thought leaders, innovators and efficient ways to bring innovative healthcare solutions to market.

EIT Health addresses these needs. It connects all relevant healthcare players across European borders – making sure to include all sides of the "knowledge triangle", so that innovation can happen at the intersection of research, education and business for the benefit of citizens. EIT Health: Together for healthy lives in Europe.

For more information visit: www.eithealth.eu

Capital Cell

Capital Cell is the first pan-European crowd-investing platform for biotech & Life Sciences companies. Mixing VC, business angels, accredited investors and the power of the Crowd, Capital Cell is building a global meeting point for companies and researchers working, fostering and financing tomorrow's medical science.

For more information visit: <https://capitalcell.es/campaign/mowoot-2021/>

For more information:

MOWOOT – info@mowoot.com - Tel: 0034935106653 – anna@mowoot.com